US Stock MarketDetailed Quotes

ELDN Eledon Pharmaceuticals

Watchlist
  • 2.060
  • -0.070-3.29%
Close Mar 28 16:00 ET
  • 2.040
  • -0.020-0.97%
Post 16:47 ET
51.12MMarket Cap-1256P/E (TTM)

About Eledon Pharmaceuticals Company

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Company Profile

SymbolELDN
Company NameEledon Pharmaceuticals
Listing Date09/17/2014
Issue Price15.00
Founded2004
CEODr. David-Alexandre C. Gros, M.D.
MarketNASDAQ
Employees17
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address19900 MacArthur Boulevard,Suite 550
CityIrvine
ProvinceCalifornia
CountryUnited States of America
Zip Code92612
Phone1-949-238-8090

Company Executives

  • Name
  • Position
  • Salary
  • Dr. David-Alexandre C. Gros, M.D.
  • Director and Chief Executive Officer
  • 604.10K
  • Paul Sean Little
  • Chief Financial Officer and Principal Accounting Officer
  • 2.18M
  • Bryan E. Smith
  • General Counsel, Corporate Secretary and Chief Compliance Officer
  • 1.68M
  • Dr. Steven N. Perrin, PhD
  • Director, President and Chief Scientific Officer
  • 3.11M
  • Keith A. Katkin
  • Chairman of the Board
  • 175.00K
  • Walter C. Ogier
  • Independent Director
  • 61.25K
  • John S. McBride
  • Independent Director
  • 65.00K
  • Dr. June Lee, M.D.
  • Independent Director
  • 60.00K
  • Dr. Jan L. Hillson
  • Independent Director
  • 282.81K
  • James Robinson
  • Independent Director
  • --
  • Dr. Allan Douglas Kirk
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg